A Pancreatic beta -Cell-specific Enhancer in the Human PDX-1 Gene Is Regulated by Hepatocyte Nuclear Factor 3beta (HNF-3beta ), HNF-1alpha , and SPs Transcription Factors*

Etti Ben-Shushan, Sonya Marshak, Michal Shoshkes, Erol Cerasi, and Danielle MelloulDagger

From the Department of Endocrinology and Metabolism, Hebrew University Hadassah Medical Center, 91120 Jerusalem, Israel

Received for publication, October 4, 2000, and in revised form, January 16, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The PDX-1 transcription factor plays a key role in pancreas development. Although expressed in all cells at the early stages, in the adult it is mainly restricted to the beta -cell. To characterize the regulatory elements and potential transcription factors necessary for human PDX-1 gene expression in beta -cells, we constructed a series of 5' and 3' deletion fragments of the 5'-flanking region of the gene, fused to the luciferase reporter gene. In this report, we identify by transient transfections in beta - and non-beta -cells a novel beta -cell-specific distal enhancer element located between -3.7 and -3.45 kilobases. DNase I footprinting analysis revealed two protected regions, one binding the transcription factors SP1 and SP3 and the other hepatocyte nuclear factor 3beta (HNF-3beta ) and HNF-1alpha . Cotransfection experiments suggest that HNF-3beta , HNF-1alpha , and SP1 are positive regulators of the herein-described human PDX-1 enhancer element. Furthermore, mutations within each motif abolished the binding of the corresponding factor(s) and dramatically impaired the enhancer activity, therefore suggesting cooperativity between these factors.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The mammalian pancreas develops by fusion of dorsal and ventral buds which form as evaginations of the upper duodenal part of the gut. Identification of the homeodomain-containing transcription factor PDX-11 as the first molecular marker temporally correlates with the pancreatic commitment of the epithelial cells in this region (1-3). Targeted inactivation of this gene in the mouse (4) as well as its mutation in man (5) results in agenesis of the pancreas. The gene is expressed both in endocrine and exocrine cells of the developing pancreas; however in the adult islet, its expression is predominantly restricted to the beta -cell (1-3), where it acts as the mediator of glucose action on insulin gene expression (6-9). In mice, beta -cell-selective disruption of pdx-1 leads to diabetes associated with reduced insulin and glucose transporter 2 expression (3).

Development, cell fate, and cell differentiation are complex events that depend on switching on and off the expression of specific sets of genes. Such regulation operates mainly at the transcriptional level by the assembly of multiprotein complexes at the enhancer(s) and the promoter regions of the gene. These complexes are formed and stabilized through multiple protein-DNA and protein-protein interactions. Since PDX-1 plays such a central role in beta -cell differentiation and function, the molecular basis of its regulation and, hence, the DNA elements and the interacting proteins involved in this process must be clarified. To this end, a 6.5-kb fragment upstream of the transcription start site of rat pdx-1/stf-1 (10) and a fragment extending from the -4.5 to +8.2-kb region of mouse pdx-1 (11) were shown to direct the expression of the beta -galactosidase reporter gene to pancreatic islet cells in transgenic mice. In transiently transfected beta -cells, appropriate expression of the rat pdx-1 gene depended in part on a proximal E box that predominantly binds the ubiquitous transcription factor USF1 (10). Tissue-specific regulation also appeared to require a distal enhancer sequence located between the -6.2- and -5.67-kb region of the rat pdx-1 gene. Analysis of the factors bound to this element indicated that the endodermal factors HNF-3beta and Neurod/Beta2 act cooperatively to induce pdx-1 expression in islet cells. Furthermore, it was shown that glucocorticoids reduce pdx-1 gene expression by interfering with HNF-3beta activity (12). Studies on the mouse pdx-1 promoter revealed that the region from -2560 to -1880 bp regulates beta -cell-specific transcription and directs the appropriate developmental and adult-specific expressions in transgenic animals. It was found that an HNF-3-like element contained within this region is important for the beta -cell specificity (11). Additional studies indicate that two highly conserved sequences in the 5'-flanking region of the PDX-1 gene (PH1/area1 and PH2/area2) confer beta -cell-specific transcriptional activity (13, 14) on a heterologous promoter. DNase I footprinting and binding analyses revealed that both sequences bind and are transactivated by HNF-3beta ; this is in accordance with the fact that its absence in mouse embryonic stem cells had a dramatic effect on pdx-1 gene expression (13). Thus, data from studies with the rat (12), the mouse (11, 13), and the human (13, 14) promoters suggest that HNF-3beta is an important regulator of pdx-1 gene transcription. Interestingly, we found that PDX-1 itself binds to the PH1/area 1 element and cooperates with HNF-3beta to activate transcription (14).

To further identify key components of importance for the expression of the human PDX-1 gene in beta -cells, we sequenced about 4.5 kb of the 5'-flanking region of the gene, constructed a series of 5' deletion fragments fused to the luciferase reporter gene, and tested them in beta - and non-beta -cells. In this report we provide evidence for a novel beta -cell-specific distal enhancer element that appears to be specific to the human PDX-1 gene. DNase I footprinting analysis revealed two protected regions: one binding the proteins identified as SP1 and SP3 and the second, the transcription factors HNF-3beta and HNF-1alpha . These are thus candidate transcription factors that are involved in regulating selective expression of the human PDX-1 gene in the adult beta -cell.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Cultures-- Hamster insulinoma HIT-T15, mouse insulinoma beta TC6, and mouse glucagonoma alpha TC1 cells were cultured in Dulbecco's modified Eagle's medium with 15% horse serum and 2.5% fetal calf serum (FCS), AR42J, HepG2, CHO, HeLa, and NIH 3T3 cells with 10% FCS. 100 units/ml penicillin and 100 mg/ml streptomycin were added to the media.

Cell Transfections-- HIT-T15, HepG2, NIH3T3, COS, and CHO cells were transfected using the calcium phosphate coprecipitation method (15), and alpha TC1, beta TC6, and AR42J cells were transfected using the Fugene transfection reagent (Roche Molecular Biochemicals) according to the manufacturer's recommendations with 1.5 µg of human PDX-1 luciferase derivatives and 0.5 µg of the internal control cytomegalovirus-beta -galactosidase DNA plasmid (CMV-beta Gal). In co-transfection experiments 1.5 µg of the reporter plasmid and 0.1-1 µg (as indicated) of the expression plasmids HNF-3alpha , HNF-3beta , HNF-1alpha , HNF-1beta , SP1, and/or SP3 were used. The cells were harvested 48 h after transfection, and about 100 µg of protein extracts were used to measure luciferase activity with the luciferase assay system (Promega, Madison, WI) and about 10 µg for the beta -galactosidase assay as described (15). Luciferase activity was measured with a luminometer (EG&G Berthold, Bad Wildbad, Germany) and normalized to beta -galactosidase values.

Plasmid Constructions-- Plasmids containing fragments of the human PDX-1 promoter were kindly provided by Alan Permutt (University of Washington, St. Louis, MO). The fragment spanning the sequences from -7 to +0.117 kb was subcloned in the pGL2 basic luciferase vector (Promega). A series of 5' and 3' deletions were performed. The PDX-1 enhancer element (Pen) was linked to the minimal thymidine kinase promoter (TK) of the herpes simplex virus subcloned into pGL2 vector. Mutations were created by polymerase chain reaction, and each construct, mut-E1 and mut-E2, was validated by sequencing.

Preparation of Cell Extracts-- Nuclear extracts were prepared as described (16). Whole cell extracts were prepared by resuspension of the cells in high salt extraction buffer (400 mM KCl, 20 mM Tris, pH 7.5, 20% glycerol, 2 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 20 µg/ml aprotinin, and 10 µg/ml leupeptin). Cell lysis was obtained by freezing and thawing, and the cellular debris was removed by centrifugation at 16,000 × g for 15 min at 4 °C. Protein concentrations were determined by the Bradford method (17).

Gel Electrophoretic Mobility Shift Assay (EMSA)-- DNA binding reactions were performed by incubating in ice for 20 min. 10 µg of whole cell extracts or nuclear extracts with 0.3 ng of 32P-labeled synthetic double-stranded oligodeoxynucleotides spanning the E1 sequence in the presence of 10 mM Hepes, pH 7.9, 10% glycerol, 50 mM KCl, 5 mM MgCl2, 5 mM dithiothreitol, 2 µg of poly(dI·dC) and 0.1% Nonidet P-40. The E2 binding reaction mixture contained 20 mM Hepes, pH 7.9, 10% glycerol, 20 mM KCl, 50 mM NaCl, 1 mM dithiothreitol, and 1 µg poly(dI·dC). Competitor oligonucleotides were incubated in a 100-fold molar excess and preincubated in the reaction mixtures for 10 min before the addition of the radiolabeled probe. Oligonucleotides were end-labeled by a fill-in reaction using the Klenow fragment of DNA polymerase I. For supershift experiments, 1 µl of antibodies were added during the preincubation period. The oligonucleotides used were: E1 (5'-TCTGCAAGCTCCGCCTCCTGGGTTCACG-3'), E1 mutant (5'-TCTGCAAGCTCCGCCgaCTatGTTCACG-3'), E2 (5'-TTCTGGGTATTTATTTATATG-3'), E2 mutant (5'-TTCTGGGTATgTAccTATATG-3'), SP1 (5'-CTAACTCCGCCCATCT-3'), and octamer (5'-CGTACTAATTTGCATTTCTA-3') consensus binding sites.

DNase I Footprint Analysis-- For DNase I footprinting assays, a fragment (-3707 to -3426) was labeled at either end by a fill-in reaction using the Klenow fragment of DNA polymerase I and [32P]dCTP to a specific activity greater than 104 cpm/ng of DNA. Probes were incubated with 20-50 µg of whole cell extracts in a 50-µl reaction mixture containing 10 mM Tris, pH 7.8, 14% glycerol, 57 mM KCl, 4 mM dithiothreitol, and 0.2 µg of poly(dI·dC). After 20 min of incubation at room temperature, 0.5-1 unit of DNase I (Promega) diluted in 50 mM MgCl2 and 10 mM CaCl2 was added for 1 min. The reaction was stopped by adding 150 µl of stop solution containing 200 mM NaCl, 20 mM EDTA, 1% sodium dodecyl sulfate, and 5 µg of yeast tRNA. DNA was extracted with phenol-chloroform, ethanol-precipitated, and analyzed on a denaturing 6% polyacrylamide gel. Sequencing reactions of each probe were performed using the Maxam and Gilbert procedure (18).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Human PDX-1 Sequences Involved in beta -Cell-specific Transcriptional Activity-- To delineate the putative DNA sequences controlling PDX-1 gene expression, we linked a fragment extending from about -7 to +0.117 kb of the 5'-flanking region of human PDX-1 to luciferase reporter gene and constructed a series of 5' deletions, as depicted in Fig. 1. The chimeric genes were transiently transfected into HIT-T15 beta -cells and CHO cells. Expression was strongly beta -cell preferential, as shown in Fig. 1. Deletion of sequences between -7 and -3.7 kb led to an approximate 2-fold increase in luciferase activity in HIT-T15 but not in CHO cells, implying the removal of a negative regulatory element(s). When an additional deletion of the distal region located between -3.7 and -2.3 kb was performed, the activity dropped by about 75%, suggesting the presence of a strong positive regulatory element. Further removal of sequences up to -160 bp had no significant effect. In contrast, deletion of the proximal region between -160 and -100 bp abolished the transcriptional activity in both cell lines (Rref. 10 and data not shown). In summary, this data indicate that the 3.7-kb fragment contains a strong positive regulatory region that confers beta -cell-specific expression on the reporter gene.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 1.   5'-Deletion analysis of the upstream human PDX-1 promoter region fused to luciferase reporter gene. The various constructs were transiently transfected into HIT-T15 or CHO cells. Luciferase activity was normalized to the control beta -galactosidase values. The human PDX-1 promoter activity in HIT-T15 cells is given relative to the promotorless basic luciferase plasmid. Numbers are relative to the S1 start site as determined for the rat gene (10). The results represent the mean of 5-11 experiments (± S.E.).

The Human PDX-1 Sequence -3.7 to -3.45 kb Acts as a beta -Cell-specific Enhancer Element-- To localize the sequences responsible for the activity delineated in Fig. 1, the fragment extending from -3.7 to 2.3 kb was subcloned directly upstream of the minimal PDX-1 promoter (-160/+117) fused to the luciferase gene. In transiently transfected HIT-T15 cells, an approximate 6-fold induction in transcriptional activity was observed (Fig. 2A). However, 5' deletion of sequences between -3.7 and -3.3 kb reduced the transcriptional activity to basal promoter levels. To further delineate the regulatory sequences contained within this 400-bp fragment, 3' deletions were generated; transient transfections revealed the presence of a positive regulatory element spanning the region from -3.7 to -3.45 kb. This element had the characteristics of an enhancer as it strongly transactivated the PDX-1 promoter when cloned in either orientation upstream of the minimal thymidine kinase promoter (Fig. 2A). Confirming its role as a tissue-specific enhancer, this 250-bp fragment strongly stimulated beta -cell-specific expression of the luciferase reporter gene in transfected beta -cells, HIT-T15 (80-fold) and beta TC6 (34-fold) versus non beta -cells, the exocrine AR42J (no activation), the glucagonoma alpha TC1 (3-fold), CHO (5-fold), and the hepatoma HepG2 (10-fold) cells (Fig. 2B). From this analysis it emerges that there is a new distal beta -cell-specific enhancer located between -3.7 and -3.45 kb. This element appears to be specific to the human PDX-1 gene as no sequence homology was found in the vicinity of this region in the mouse gene (not shown).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 2.   Deletion analysis of human PDX-1 distal regulatory sequences. A, the fragment extending from -3.7 to -2.3 kb (solid line) was subcloned upstream of the human PDX-1 minimal promoter (-160 bp) (hatched) linked to the reporter luciferase gene. The truncated plasmids were transiently transfected into HIT-T15 cells (see legend of Fig. 1). Results represent the mean of 6-10 experiments (±S.E.). B, the PDX-1 sequence from -3.7 to -3.45 kb acts as a beta -cell-specific enhancer element. The distal 250-bp element (PEn for PDX-1 enhancer) was cloned upstream of the thymidine kinase promoter linked to the luciferase reporter gene as well as the parental TK-Luc and transiently transfected into beta -cells, HIT-T15 and beta TC6, and non-beta -cells, AR42J, alpha TC1, CHO, and HepG2. Luciferase activity was normalized to the control beta -galactosidase values and shown relative to the basic TK-Luc vector. The results represent the mean of 3-6 experiments (±S.E.).

DNase I Footprinting of the Human PDX-1 beta -Cell-specific Enhancer Element-- The transcriptional activity driven by the distal enhancer element of human PDX-1 suggested the presence of cis-acting regulatory elements in this region. To assess whether such putative elements interact with specific proteins, we performed DNase I footprinting analysis using the fragment extending from -3.7 to -3.3 kb as a probe and extracts from HIT-T15 and CHO cells. As shown in Fig. 3A, two protected regions were obtained. The pattern of the first protected sequence E1, -3.473/-3.494 kb, shows a hypersensitive site in the presence of HIT-T15 cell extracts. The second footprinted sequence, between -3.565 and -3.590 kb, E2, occurs within a particularly AT-rich region and shows a slightly different digestion pattern in HIT-T15 and CHO cell extracts. The sequence of the human PDX-1 enhancer element (-3.7/-3.45 kb) is presented in Fig. 3B with the footprinted regions underlined. To further characterize the trans-acting factors binding to the footprinted regions, double-stranded oligonucleotides spanning these sequences were synthesized and used as probes to detect HIT-T15 and CHO proteins by electrophoretic mobility shift assay.


View larger version (49K):
[in this window]
[in a new window]
 
Fig. 3.   DNase I footprinting analysis of the human enhancer element. A, the analysis was performed using the end-labeled fragment spanning the sequences between approximately -3.7 and -3.4 kb and incubated with no extracts (lanes 2, 3, and 9), with extracts from HIT (lanes 4, 5, and 10), or CHO (lanes 6, 7, and 11) cells. G+A and C+T sequencing reactions were run alongside as a marker (lanes 1 and 8, respectively). B, nucleotide sequence of the beta -cell-specific enhancer in the human PDX-1 gene. The E1 and E2 footprinted regions are indicated.

Members of the SP1 Family of Proteins Interact with the E1 Sequence of the Human PDX-1 Enhancer-- Using the E1 sequence as a probe, two binding complexes (a and b in Fig. 4A) were obtained in HIT cell extracts. Computer analysis for potential binding sequences (19) revealed a GC-box element. To assess whether this motif could interfere with the formation of the E1 complexes, excess unlabeled oligonucleotide containing the SP1 consensus motif GGGCGG was added to the binding reaction. The DNA complexes were competed away by the SP1 oligonucleotide (Fig. 4A, lane 3) but not by a nonspecific one (Fig. 4A, lane 4). To confirm that SP1 family members are involved in E1 complexes, specific SP1 and SP3 antibodies were added separately (Fig. 4B, lanes 6 and 7, respectively) or simultaneously (Fig. 4B, lane 8) to the binding reactions. The results demonstrate that the slower migrating complex a was recognized by anti-SP1 (Fig. 4B, lane 6), whereas complex b reacted with anti SP3 (Fig. 4B, lane 7) antibodies.


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 4.   SP1 and SP3 from HIT cells bind the E1 sequence of the human PDX-1 enhancer element. A, EMSA was performed using CHO (lane 1) or HIT (lane 2) cell extracts and a 32P-labeled E1 sequence. Two complexes were formed, labeled a and b, indicated by arrows. Competition for binding of HIT cell extracts to the labeled E1 sequence was performed with a 100-fold excess of an unlabeled oligonucleotide containing an SP1 consensus motif (SP1, lane 3) or with a nonspecific oligonucleotide (ns, lane 4). B, identification of SP1 and SP3 complexes. EMSA was performed with HIT-T15 cell extracts incubated with the labeled E1 sequence (lane 5) in the presence of antiserum against SP1 (lane 6) or SP3 (lane 7) or both (lane 8) or preimmune serum (PIS, lane 9).

The Transcription Factors HNF-3beta and HNF-1alpha Interact with the E2 Sequence of the Human PDX-1 Enhancer-- In EMSA, using the E2 sequences with HIT-T15 or beta TC6 cell extracts, a faint complex labeled a and a strong faster migrating b complex were detected (Fig. 5A). The b complex was observed in all pancreatic cells tested, i.e. the glucagonoma alpha TC1 and the exocrine AR42J line as well as in the hepatic HepG2 cells. In contrast, the a complex was mainly observed in beta -cells; a closely migrating complex in AR42J and HepG2 cells runs slightly faster. E2 is contained within an AT-rich region (Fig. 3B), and computer analysis for transcription factors unveiled potential binding sites for several homeodomain-containing proteins (19) including overlapping motifs for HNF-3 and HNF-1. To determine whether HNF-3 or HNF-1 is involved in the observed complexes, electrophoretic mobility shift assays were performed using either the wild type E2 sequence (wt-E2) or the mutant form containing a modified HNF-3/HNF-1 motif (mut-E2). The DNA complexes a and b observed in HIT-T15 cells were competed away by excess of unlabeled wild type oligonucleotide (Fig. 5B, lane 3). In contrast, the unlabeled oligonucleotide containing the mutated HNF-3/HNF-1 motifs (Fig. 5B, lane 4) or a nonspecific (octamer consensus motif) oligonucleotide showed no competition (Fig. 5B, lane 5). When the mutated HNF-3/HNF-1 sequence was used as probe, the a and b complexes were abrogated (Fig. 5B, lane 7).


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 5.   HNF-1alpha and HNF-3beta in beta -cells interact with the E2 sequence of the human PDX-1 enhancer element. A, EMSA was performed using HIT-T15 (lane 1), beta TC6 (lane 2), alpha TC1 (lane 3), AR42J (lane 4), HepG2 (lane 5), HeLa (lane 6), CHO (lane 7), or NIH 3T3 (lane 8) cell extracts and a 32P-labeled E2 sequence. Two complexes in beta -cells, labeled a and b, are indicated by arrows. NE, nuclear extracts. B, competition for binding of HIT cell extracts to the wild type labeled E2 sequence (Wt-E2) with a 100-fold excess of an unlabeled oligonucleotide (lane 3), excess HNF-3/HNF-1 mutated site (E2mut, lane 4), or with a nonspecific oligonucleotide (ns, lane 5). The E2 sequence carrying a mutated HNF-3/HNF-1 was used as probe with CHO (lane 6) and HIT (lane 7) cell extracts. C, The a complex corresponds to HNF-1alpha , and the b complex corresponds to HNF-3beta . EMSA was performed with HIT-T15 cell extracts incubated with the labeled E2 sequence (lane 1) in the presence of preimmune serum (PIS, lane 2), or antiserum against HNF-3alpha (lane 3), HNF-3beta (lane 4), HNF-1alpha (lane 5), or HNF-1beta (lane 6).

To verify the presence of HNF-3beta and HNF-1alpha in the E2 complexes, their ability to interact with a series of antibodies was tested. Fig. 5C demonstrates that the b complex is specifically recognized by antibodies against HNF-3beta (Fig. 5C, lane 4) but not with anti-HNF-3alpha (Fig. 5C, lane 3) or antibodies against the homeodomain proteins PDX-1, Oct-4, cdx2/3, Nkx6.1, or isl-1 (data not shown). Furthermore, the a complex interacted with anti- HNF-1alpha (lane 5) but not with anti-HNF-1beta (lane 6) antibodies. Cell extracts from COS cells transfected with an expression plasmid for HNF-3beta or HNF-1alpha were analyzed for their interaction with the E2 sequence to establish that the protein contained in the b complex corresponds to HNF-3beta . Indeed, the HNF-3beta and HNF-1alpha complexes in COS cells migrated similarly to the a or b complex in HIT cells, respectively, and were also recognized by the corresponding antibodies (data not shown). Taken together, these results demonstrate that the endogenous HNF-1alpha and HNF-3beta in HIT-T15 cells specifically bind the E2 sequence.

Combinatorial Effects of HNF-1alpha , SP1, SP3, and HNF-3beta in the Activation of the Human PDX-1 Enhancer Element-- To investigate the effect of the above transcription factors on gene expression driven by the enhancer element, we performed transient transfection experiments in NIH3T3 cells. To this end, the PEn-TK-luciferase construct was cotransfected with increasing amounts of the HNF-1alpha and HNF-1beta plasmids separately or in combination with HNF-3beta expression plasmid (Fig. 6A). In parallel, we carried out similar experiments with SP1 and SP3 expression plasmids (Fig. 6B). As presented in Fig. 6A, HNF-3beta and HNF-1alpha but not HNF-1beta separately stimulated the PDX-1 enhancer activity in a dose-dependent manner. Furthermore, cotransfection with HNF-3beta and increasing amounts of HNF-1alpha cooperatively activated the expression of the gene. Similarly, HNF-3beta and SP1 individually activated the chimeric gene, and cotransfection with a constant amount of HNF-3beta and increasing amounts of SP1 significantly stimulated the expression of the gene in a more than additive manner. In contrast, although SP3 lacked any effect on the enhancer activity when acting independently, it dramatically suppressed the HNF-3beta -mediated transactivation (Fig. 6B).


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 6.   Interactive transactivation of the human PDX-1 enhancer element by HNF-3beta , SP1/3 and HNF-1alpha /beta in non beta -cells. A, NIH3T3 cells were transiently cotransfected with HNF-1beta (dotted bars), HNF-1alpha (hatched bars), or HNF-3beta (black bar) separately or cotransfected with a constant amount of HNF-3beta and increasing amounts of HNF-1beta (gray bars) or HNF-1alpha (dark hatched bars) and the wild type PEn-TKLuc. B, same as in A where transfections were carried out with SP1 (dotted bars), SP3 (hatched bars), or HNF-3beta (black bar) separately or HNF-3beta co-transfected with increasing amounts of SP1 (gray bars) or SP3 (dark hatched bars). Luciferase activity was normalized to the control beta -galactosidase values and shown relative to the basic PEn-TKLuc vector. The results are the mean of four representative experiments. C, effects of mutations in the SP1 and HNF-3beta motifs on the human PDX-1 enhancer activity. The PEn-TKLuc (empty bar) and the derived constructs carrying mutations in the SP1 (mut-E1, dotted bar) or the HNF-3beta (mut-E2, hatched bar) binding sites were transiently transfected in HIT-T15 cells. The results represent the mean of seven experiments (±S.E.). D, transactivation with HNF-3beta in non-beta -cells. CHO cells were transiently cotransfected with 0.1 µg of HNF-3beta expression plasmid (black bars) or empty vector (hatched bars) and either the wild type PEn-TKLuc or the derived mut-E2 constructs. Luciferase activity was normalized to the control beta -galactosidase values and shown relative to the basic TK-Luc vector. The results represent are mean of n = 4 (±S.E.).

Mutant constructs were created to specifically alter the SP1 or HNF-3beta /HNF-1 motifs in the context of the human PDX-1 enhancer element (Pen) linked to the luciferase reporter gene and driven by the minimal TK promoter. The mutation that eliminated SP1/SP3 binding (mut-E1) caused more than 90% reduction in enhancer activity in HIT-T15 cells (Fig. 6C). Mutation in the overlapping HNF-3beta /HNF-1 motifs (mut-E2) also caused an 80% decrease in enhancer activity. The effect of HNF-3beta on enhancer activity was further examined by cotransfection experiments in CHO cells using the wild type reporter construct (PEn) or the E2 mutant form carrying a modified HNF-3beta /HNF-1 site (mut-E2) together with an HNF-3beta expression vector. About 10-fold activation was detected using the wild type enhancer, but only 2-fold increase was detected with the mutant reporter construct (Fig. 6D). Similar experiments showed that HNF-1alpha transactivated the wild type enhancer by about 2-fold but had almost no effect on the mutated element (not shown). The data presented thus suggest that the transcription factors HNF-3beta , HNF-1alpha , SP1, and SP3 are regulators of the herein-described human PDX-1 enhancer element.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

It is accepted that PDX-1 functions as a master regulator of the exocrine and endocrine pancreatic programs. The pdx-1 gene is expressed early during development in cells of both origins, whereas later it becomes restricted mainly to beta -cells. Fragments containing -6.5- and -4.5 kb- sequences of the rat (10) and the mouse (11) pdx-1 gene, respectively, were sufficient in targeting its expression to rodent islet cells. Therefore, to further characterize the potential regulatory elements of the human PDX-1 gene, we analyzed about 4.5 kb in the 5'-flanking region of the gene. By transient transfections of beta -cell and non-beta -cell lines with different 5' and 3' deletions, a strong beta -cell-specific enhancer element located between -3.7 and -3.45 kb was demonstrated. The 4.5-kb 5'-flanking sequences of the human and mouse pdx-1 genes are markedly different, apart from the conserved proximal promoter region; only three short highly homologous areas located 3' of the herein-described enhancer element are observed. No homology was observed between this enhancer and the one previously described further upstream in the rat gene (12). These observations suggest that several regulatory elements in pdx-1 gene contribute to its beta -cell-specific expression.

To identify the potential transcription factors that bind the distal enhancer element, DNase I footprint analysis was performed, and two protected regions (E1 and E2) were identified. The E1 area was found to bind the transcription factors SP1 and SP3. These factors bind DNA with similar specificity and affinity. SP1 is expressed in most tissues, and targeted inactivation of the gene in the mouse results in retarded growth of the embryos, which die early during gestation (20). Many genes are controlled by SP1, which in some cases acts cooperatively with other transcription factors (21). SP3 has been shown to function either as an inhibitor by competing with SP1 for binding to DNA (22, 23) or as an activator, depending on promoter context and cell type (23, 24). It has also been suggested that the relative amounts of SP1 and SP3 can vary during cellular differentiation, thus modulating the response of target genes (see review, see Ref. 25). High levels of SP1 were found in hemapoietic stem cells, fetal cells, and spermatids (20). We also observed about twice as much SP1 protein in pancreatic cells than in fibroblasts but similar levels of SP3 in all tested cells (data not shown). Furthermore, in this report we show that in transfected fibroblasts, whereas excess SP1 has a stimulatory effect on the enhancer transcriptional activity, SP3 shows a rather inhibitory effect on transcription, mainly by inhibiting HNF-3beta -mediated transactivation.

The E2 protected area is contained within an AT-rich sequence, and factors binding this region were identified as HNF-3beta and HNF-1alpha . The important role of HNF-3beta in transactivating the conserved regulatory elements in the mouse and human pdx-1 5'-flanking region was recently shown (13, 14), and its absence in mouse embryonic stem cells dramatically impaired pdx-1 gene expression (13). Moreover, the distal enhancer element identified in the rat pdx-1 (stf-1) gene binds HNF-3beta and Neurod/Beta2 factors, which cooperatively induce its expression in islet cells. It was further shown that glucocorticoid-induced reduction of pdx-1 expression was mediated by impaired HNF-3beta activity (12). HNF-3beta belongs to the forkhead/winged helix family of transcription factors and is essential for endodermal cell lineages (26-28). Since HNF-3beta is not restricted to beta -cells, selective transcription of pdx-1 must an require additional factor(s). It is believed that HNF-3beta , by its structural similarity to histone H5, may alter nucleosomal structure, thus facilitating gene transcription by opening the chromatin structure and thereby providing access to other transcription factors (29, 30). Whereas HNF-3beta binds as a monomer, members of HNF1 family of transcription factors bind DNA as homo- or heterodimers (31). HNF-1alpha and HNF-1beta are hepatocyte-enriched transcription factors that are also expressed in other tissues like in the pancreas. The relative abundance of these two proteins differs markedly between the different pancreatic cell lines (Fig. 5A and data not shown). It is conceivable that the relative levels of HNF1 subtypes may also be one of the factors contributing to the tissue specific expression of the PDX-1 gene, as it has been recently shown for the regulation of glucose transporter 2 (Glut2) gene in hepatocytes and beta -cells (32). The relative levels of these two proteins have also been reported to affect vitamin D binding protein gene transcription. Although HNF-1alpha had a stimulatory effect, HNF-1beta acted as an inhibitor of HNF-1alpha -transactivating potency (33).

Our findings that the enhancer element binds HNF-3beta /HNF-1alpha and SP1/SP3 and that mutations in each site dramatically impair its transcriptional activity suggest cooperativity between these factors. Cooperativity between SP1 and members of HNF3 family has also been demonstrated for the surfactant protein B (34) and for the uteroglobin/CC10 (35) genes in the lung epithelium. Hence, SP1 could function as a bridging factor between the hepatic nuclear factors and the basal transcriptional machinery, or conversely, HNF-3beta may facilitate HNF-1alpha and SP1 binding by bending the DNA.

Since HNF-3beta /HNF-1alpha and SP1 seem equally important for the human PDX-1 promoter activity, the synergism and possible interactions between these factors need to be analyzed. Nevertheless, HNF-3beta , HNF-1alpha , and SP1 are also present in other pancreatic and hepatic cells, and yet the human PDX-1 enhancer activity was low in these cells, pointing to the possibility that other accessory proteins and/or an additional level of transcriptional control may contribute to the beta -specific transcriptional activity of the PDX-1 gene. Transcriptional regulation appears to be a multistep process that may also involve chromatin remodeling, e.g. the methylation status of CpG sequences in a control element (36, 37). Findings showing that methylation of SP1 sites might be a relatively common and physiological mechanism of gene repression have been reported for leukosielin (CD43) (38, 39), cyclin D1 (40), and lung epithelial T1alpha genes in nonexpressing cells (41). SP1 elements have also been shown to play a key role in protecting a CpG island in the adenine phosphoribosyltransferase (APRT) gene from de novo methylation (37, 42). The effect of methylation on the identified enhancer element transcriptional activity needs to be tested.

We demonstrate that an AT-rich and a GC-box sequences are the major sites of regulation for the herein-described human PDX-1 enhancer element. We suggest that the transcriptional stimulation of pdx-1 gene in beta -cells is mediated by a unique combination of protein-protein interactions and that separate modules in its sequence could be active at a given stage by binding a specific set of transcription factors. Indeed, the transcription factors HNF-3beta , HNF-1alpha , HNF-1beta , SP1, and PDX-1 itself, which regulate the expression of the PDX-1 gene, have been previously shown, mainly by knockout in mice, to be important developmental regulators.

Recently, mutations in genes coding for three members of the HNF family of proteins have been identified in a subset of type 2 diabetes, MODY (maturity-onset diabetes of the young), HNF-1alpha (MODY3) (43), HNF-1beta (MODY5) (44), and HNF-4alpha (MODY1) (45). Thus, genes coding for the transcription factors controlling PDX-1 gene expression may be candidates for susceptibility to diabetes.

    ACKNOWLEDGEMENTS

We thank Dr. Alan M. Permutt (Washington University) for the human PDX-1 gene. We are infinitely grateful to Dr. Robert Costa (University of Illinois at Chicago, IL) for the gifts of HNF-3alpha and HNF-3beta expression vectors and antibodies, Dr. Guntram Suske (Marburg, Germany) for SP1 and SP3 expression vectors and antibodies, Dr. Moshe Yaniv (Paris, France) for HNF-1alpha and HNF-1beta expression vectors and antibodies, and Dr. Ariella Openheim for SP1 consensus oligonucleotide. Our sincere thanks to Rahel Oron for excellent technical help and Dr. Leora Havin for helpful discussion.

    FOOTNOTES

* This work was supported by grants from the Juvenile Diabetes Foundation International and the Israel Science Foundation and the European Commission (BIOMED2).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) 225952.

Dagger To whom correspondence should be addressed: Dept. of Endocrinology and Metabolism, Hadassah University Hospital, P. O. Box 12000, Jerusalem 91120, Israel. Tel.: 972-2-677 83 98; Fax: 972-2-643 79 40; E-mail: Danielle@md2.huji.ac.il.

Published, JBC Papers in Press, February 5, 2001, DOI 10.1074/jbc.M009088200

    ABBREVIATIONS

The abbreviations used are: PDX, pancreatic duodenal homeobox; kb, kilobase(s); bp, base pair(s); Luc, Luciferase; HNF, hepatocyte nuclear factor; CHO, Chinese hamster ovary; TK, thymidine kinase; EMSA, electrophoretic mobility shift assay.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Guz, Y., Montminy, M. R., Stein, R., Leonard, J., Gamer, L. W., Wright, C. V., and Teitelman, G. (1995) Development 121, 11-18[Abstract/Free Full Text]
2. Ahlgren, U., Jonsson, J., and Edlund, H. (1996) Development 122, 1409-1416[Abstract/Free Full Text]
3. Ahlgren, U., Jonsson, J., Jonsson, L., Simu, K., and Edlund, H. (1998) Genes Dev. 12, 1763-1768[Abstract/Free Full Text]
4. Jonsson, J., Carlsson, L., Edlund, T., and Edlund, H. (1994) Nature 371, 606-609[CrossRef][Medline] [Order article via Infotrieve]
5. Stoffers, D. A., Zinkin, N. T., Stanojevic, V., Clarke, W. L., and Habener, J. F. (1997) Nat. Genet. 15, 106-110[Medline] [Order article via Infotrieve]
6. Melloul, D., Ben-Neriah, Y., and Cerasi, E. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 3865-3869[Abstract]
7. Petersen, H. V., Serup, P., Leonard, J., Michelsen, B. K., and Madsen, O. D. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 10465-10469[Abstract/Free Full Text]
8. Marshak, S., Totary, H., Cerasi, E., and Melloul, D. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 15057-15062[Abstract/Free Full Text]
9. MacFarlane, W. M., Read, M. L., Gilligan, M., Bujalska, I., and Docherty, K. (1994) Biochem. J. 303, 625-631[Medline] [Order article via Infotrieve]
10. Sharma, S., Leonard, J., Lee, S., Chapman, H. D., Leiter, E. H., and Montminy, M. R. (1996) J. Biol. Chem. 271, 2294-2299[Abstract/Free Full Text]
11. Wu, K. L., Gannon, M., Peshavaria, M., Offield, M. F., Henderson, E., Ray, M., Marks, A., Gamer, L. W., Wright, C. V., and Stein, R. (1997) Mol. Cell. Biol. 17, 6002-6013[Abstract]
12. Sharma, S., Jhala, U. S., Johnson, T., Ferreri, K., Leonard, J., and Montminy, M. (1997) Mol. Cell. Biol. 17, 2598-2604[Abstract]
13. Gerrish, K., Gannon, M., Shih, D., Henderson, E., Stoffel, M., Wright, C. V., and Stein, R. (2000) J. Biol. Chem. 275, 3485-3492[Abstract/Free Full Text]
14. Marshak, S., Benshushan, E., Shoshkes, M., Havin, L., Cerasi, E., and Melloul, D. (2000) Mol. Cell. Biol. 20, 7583-7590[Abstract/Free Full Text]
15. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, pp. 16.33-16.36 and 16.66-16.67, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
16. Schreiber, E., Matthias, P., Muller, M. M., and Schaffner, W. (1989) Nucleic Acids Res. 17, 6419[Medline] [Order article via Infotrieve]
17. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254[CrossRef][Medline] [Order article via Infotrieve]
18. Maxam, A. M., and Gilbert, W. (1980) Methods Enzymol. 65, 499-560[Medline] [Order article via Infotrieve]
19. Wingender, E., Dietze, P., Karas, H., and Knuppel, R. (1996) Nucleic Acids Res. 24, 238-241[Abstract/Free Full Text]
20. Saffer, J. D., Jackson, S. P., and Annarella, M. B. (1991) Mol. Cell. Biol. 11, 2189-2199[Medline] [Order article via Infotrieve]
21. Pugh, B. F., and Tjian, R. (1990) Cell 61, 1187-1197[Medline] [Order article via Infotrieve]
22. Conn, K. J., Rich, C. B., Jensen, D. E., Fontanilla, M. R., Bashir, M. M., Rosenbloom, J., and Foster, J. A. (1996) J. Biol. Chem. 271, 28853-28860[Abstract/Free Full Text]
23. Majello, B., De Luca, P., and Lania, L. (1997) J. Biol. Chem. 272, 4021-4026[Abstract/Free Full Text]
24. Ihn, H., and Trojanowska, M. (1997) Nucleic Acids Res. 25, 3712-3717[Abstract/Free Full Text]
25. Philipsen, S., and Suske, G. (1999) Nucleic Acids Res. 27, 2991-3000[Abstract/Free Full Text]
26. Zaret, K. S. (1996) Annu. Rev. Physiol. 58, 231-251[CrossRef][Medline] [Order article via Infotrieve]
27. Gualdi, R., Bossard, P., Zheng, M., Hamada, Y., Coleman, J. R., and Zaret, K. S. (1996) Genes Dev. 10, 1670-1682[Abstract]
28. Levinson-Dushnik, M., and Benvenisty, N. (1997) Mol. Cell. Biol. 17, 3817-3822[Abstract]
29. Clark, K. L., Halay, E. D., Lai, E., and Burley, S. K. (1993) Nature 364, 412-420[CrossRef][Medline] [Order article via Infotrieve]
30. Shim, E. Y., Woodcock, C., and Zaret, K. S. (1998) Genes Dev. 12, 5-10[Abstract/Free Full Text]
31. Mendel, D. B., Hansen, L. P., Graves, M. K., Conley, P. B., and Crabtree, G. R. (1991) Genes Dev. 5, 1042-1056[Abstract]
32. Cha, J. Y., Kim, H., Kim, K. S., Hur, M. W., and Ahn, Y. (2000) J. Biol. Chem. 275, 18358-18365[Abstract/Free Full Text]
33. Song, Y. H., Ray, K., Liebhaber, S. A., and Cooke, N. E. (1998) J. Biol. Chem. 273, 28408-28418[Abstract/Free Full Text]
34. Margana, R. K., and Boggaram, V. (1997) J. Biol. Chem. 272, 3083-3090[Abstract/Free Full Text]
35. Braun, H., and Suske, G. (1998) J. Biol. Chem. 273, 9821-9828[Abstract/Free Full Text]
36. Brandeis, M., Ariel, M., and Cedar, H. (1993) Bioessays 15, 709-713[Medline] [Order article via Infotrieve]
37. Brandeis, M., Frank, D., Keshet, I., Siegfried, Z., Mendelsohn, M., Nemes, A., Temper, V., Razin, A., and Cedar, H. (1994) Nature 371, 435-438[CrossRef][Medline] [Order article via Infotrieve]
38. Kudo, S., and Fukuda, M. (1995) J. Biol. Chem. 270, 13298-13302[Abstract/Free Full Text]
39. Kudo, S. (1998) Mol. Cell. Biol. 18, 5492-5499[Abstract/Free Full Text]
40. Kitazawa, S., Kitazawa, R., and Maeda, S. (1999) J. Biol. Chem. 274, 28787-28793[Abstract/Free Full Text]
41. Cao, Y. X., Jean, J. C., and Williams, M. C. (2000) Biochem. J. 350, 883-890[CrossRef][Medline] [Order article via Infotrieve]
42. Macleod, D., Charlton, J., Mullins, J., and Bird, A. P. (1994) Genes Dev. 8, 2282-2292[Abstract]
43. Yamagata, K., Oda, N., Kaisaki, P. J., Menzel, S., Furuta, H., Vaxillaire, M., Southam, L., Cox, R. D., Lathrop, G. M., Boriraj, V. V., Chen, X., Cox, N. J., Oda, Y., Yano, H., Le Beau, M. M., Yamada, S., Nishigori, H., Takeda, J., Fajans, S. S., Hattersley, A. T., Iwasaki, N., Hansen, T., Pedersen, O., Polonsky, K. S., Turner, R. C., Velho, G., Chevre, J-C., Froguel, P., and Bell, G. I. (1996) Nature 384, 455-458[CrossRef][Medline] [Order article via Infotrieve]
44. Horikawa, Y., Iwasaki, N., Hara, M., Furuta, H., Hinokio, Y., Cockburn, B. N., Lindner, T., Yamagata, K., Ogata, M., Tomonaga, O., Kuroki, H., Kasahara, T., Iwamoto, Y., and Bell, G. I. (1997) Nat. Genet. 17, 384-385[Medline] [Order article via Infotrieve]
45. Yamagata, K., Furuta, H., Oda, N., Kaisaki, P. J., Menzel, S., Cox, N. J., Fajans, S. S., Signorini, S., Stoffel, M., and Bell, G. I. (1996) Nature 384, 458-60[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.